Published in Cancer Weekly, May 6th, 2003
"F11782 (2'',3'' bis-pentafluorophenoxyacetyl-4'',6''ethylidene-beta-D-glucoside of 4'-phosphate-4'-dimethylepipodophyllotoxin-2N-methyl glucamine salt), is a novel dual catalytic inhibitor of topoisomerases I and II characterized by marked in vivo antitumor activity, which also proved cytotoxic and exhibited DNA damaging properties in vitro," scientists in France report.
"Mechanisms associated with cell killing by F11782 have been examined in P388 leukemia cells. Treatment with F11782 resulted in a dose dependent DNA...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.